Following this blog’s recent comparison of companies developing bio/chemical targeted delivery platforms, this week’s graphic looks at a more experimental class of players: those developing advanced material delivery systems.
Advanced material delivery systems are based on novel substances to control placement and function of active ingredients. They rely on innovative approaches ranging from solid polymer shapes, alternative materials like cyclodextrins, and even blood cells harvested from the patient and loaded with drug. As a class, companies in this category are noticeably less mature than other targeted delivery companies, and they have yet to prove the value of their technology and their ability to execute.
The clear leaders are Monosol Rx and Capsulution Pharma. The former’s thin-film formulations of prescription and over-the-counter actives have led to steady growth in product development, partnerships, and sales revenue of around $10 million. Monosol also scores highly on technical value due to its product’s patient-friendly form factor and low cost compared pills or injections. Capsulution Pharma scores high technical marks for the bioavailability and loading of its solid polymer nanoparticles and polyelectrolyte-based drug delivery systems in targeting grave indications like glioblastoma. A strong management team drawn from corporations like Merck as well as start-ups helps boost Capsulation’s score on the business execution dimension.
Soy Works’ comparatively high technical score derives from the versatility and apparent effectiveness of the biodegradable plastic resins it’s developing based on soy protein. Representative applications include nutrient-releasing pots for houseplants and drug-loaded feed granules for animal medicine. The small founder-funded company is growing organically, but without partners or a cash infusion it struggles on business execution.
Source: Lux Research report “Ranking Targeted Delivery Technologies on the Lux Innovation Grid.”
facebook 
twitter 
email 
linkedin